Alnylam adds Benjamin Cravatt to board; stockholders re-elect three Class I directors
Effective June 1, 2026, Alnylam expanded its board from ten to eleven members and elected Benjamin F. Cravatt, Ph.D. to fill the new seat. At its annual meeting, stockholders re-elected three Class I directors and approved executive pay in a non-binding vote, though one director's support was notably lower than the others.
Key points
- Dr. Cravatt receives a $75,000 annual cash retainer and a stock option with a $600,000 grant date fair value.
- Stuart A. Arbuckle, Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D. were re-elected as Class I directors to serve until the 2029 annual meeting.
- Stockholders approved executive compensation with 111,772,389 votes for and 8,552,534 against.
- PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 119,847,735 votes for.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.